SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD.
Regd. Office: Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur-302015 (Raj.)
Phone: 0141-2742557, 2742266
CIN: L85110RJ1989PLC005206
E-Mail: sharmaeastindia@gmail.com
Website: www.jaipurhospital.co.in

August 12, 2026

To,
The Manager,
Corporate Relationship Department,
BSE Ltd.
25th Floor P.J. Towers,
Dalal Street, Fort,
MUMBAI-400 001

Subject: Approval of Standalone Unaudited Financial Results for the quarter ended 30th June 2026 along with Limited Review Report

Ref: Scrip Code: - 524548

Dear Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

1. Standalone Unaudited Financial Results for the quarter ended 30th June 2026.

2. Auditor Limited Review Report for the quarter ended 30th June 2026.

The Meeting of the Board of Directors of the Company commenced at 5.30 p.m. (IST) and concluded at 6.15 p.m. (IST).

Thanking You

For Sharma East India Hospitals & Medical Research Limited

Bhawana Sharma
(Company Secretary
and Compliance Officer)
M. No. A61665

Encl.: As above.

Independent Auditor's Limited Review Report on Unaudited Quarterly Standalone Financial Results for the Quarter ended 30.06.2026 of the Company, M/s. Sharma East India Hospitals & Medical Research Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors
Sharma East India Hospitals & Medical Research Ltd.

1. We have reviewed the accompanying Statement of Un-audited Standalone Financial Results of Sharma East India Hospitals & Medical Research Limited (the "company") for the Quarter ended 30.06.2026 being submitted by the company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended), including relevant circulars issued by the SEBI from time to time.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended). Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act 2013, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit and

hence review provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR GOPAL SHARMA & CO.
CHARTERED ACCOUNTANTS

GAUTAM SHARMA
Digitally signed by GAUTAM SHARMA
Date: 2026.08.12 18:31:03 +05'30'

(CA GAUTAM SHARMA)
PARTNER
Membership No. 079225
Firm Registration No. 002803C
UDIN: 26079225ZLSQDR8019

Place: Jaipur
Date: 12.08.2026

SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED
NEAR SMS STADIUM, LAL KOTHI, TONK ROAD
JAIPUR
CIN: L85110RJ1989PLC005206

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2026 (Rs. In lakhs, Except per share Data)

S. No.	Particulars	Quarter Ended			Year Ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Income from Operations				
(a)	Revenue from Operations	1,076.47	746.60	947.37	3,593.30
(b)	Other Income	3.75	2.11	4.00	15.61
	Total Revenue	1,080.22	748.71	951.37	3,608.91
2	Expenses				
(a)	Cost of materials consumed	211.40	16.22	182.80	540.11
(b)	Purchase of stock in trade	277.13	226.67	220.95	898.05
(c)	Change in Inventories of stock in trade	-	(2.71)	-	(2.71)
(d)	Employee benefits expenses	134.04	121.47	122.88	500.36
(e)	Finance cost	18.78	16.48	11.25	51.09
(f)	Depreciation and amortisation expense	35.70	43.75	42.29	171.96
(g)	Share of consultants	223.19	204.29	214.12	877.48
(h)	Accomodation and Surgery Expenses	17.50	34.28	-	34.28
(i)	Other Expenses	127.32	45.30	114.10	381.87
	Total Expenses	1,045.06	705.75	908.39	3,452.49
3	Profit/(Loss) before exceptional items & tax (1-2)	35.16	42.96	42.98	156.42
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before tax (3-4)	35.16	42.96	42.98	156.42
6	Tax expense				
	Current tax / MAT	9.14	4.77	13.77	42.07
	Taxation for Earlier years	-	-	-	-
	Deferred tax	-	(4.73)	(2.59)	(9.92)
	Total Tax Expenses	9.14	0.04	11.18	32.15
7	Profit/(Loss) for the period (5-6)	26.02	42.92	31.80	124.27
8	Other Comprehensive Income				
	Changes in fair value of investments in equity shares carried at fair value through OCI				
(i)	Items that will not be reclassified to profit or loss	-	-	-	-
(ii)	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	
	Other Comprehensive Income for the period	-	-	-	-
9	Total Comprehensive Income (7+8)	26.02	42.92	31.80	124.27
10	Paid up equity share capital (face value of Rs. 10/- each)	328.38	328.38	328.38	328.38
11	Earnings per share				
	Basic	0.79	1.31	0.97	3.78
	Diluted	0.79	1.31	0.97	3.78

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LIMITED
JAIPUR

Notes :-

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 12th August, 2026. The statutory Auditors have carried out Limited Review of above Financial Results.
2. The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBIHO/DDHS/CIR/P/2018/144 Dated "26 November, 2018."
3. The figures of the previous period / year have been re-grouped /re-arranged and / or recast wherever found necessary.
4. These results have been prepared in accordance with Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended), including relevant circulars issued by the SEBI from time to time.

For **SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED**

Shailendra Kumar Sharma
(Managing Director)
DIN 00432070

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LIMITED ★ JAIPUR

12.08.2026

At Jaipur